Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Phillips, Robert S ^a   Wade, Ros ^a   Lehrnbecher, Thomas ^b   Stewart, Lesley A ^a   Sutton, Alex J ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ARTICLE; CINAHL; EMBASE; ERYTHROCYTE SEDIMENTATION RATE; FEBRILE NEUTROPENIA; HUMAN; MEDLINE; META ANALYSIS; NEOPLASM; PREDICTIVE VALUE; SYSTEMATIC REVIEW; ADOLESCENT; BLOOD; CHILD; FEVER; METABOLISM; NEUTROPENIA; RECEIVER OPERATING CHARACTERISTIC; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; C-REACTIVE PROTEIN; CHILD; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; ROC CURVE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855894765     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-6     Document Type: Article

References (54)

1. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JWW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer 2006, 42:2183-2190. 10.1016/j.ejca.2006.06.006, 16919780.
2. Freycon F, Trombert-Paviot B. Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: a follow-up of patients included in the childhood cancer registry of the Rhone-Alpes region in France (ARCERRA). Pediatr Blood Cancer 2008, 50:1213-1220. 10.1002/pbc.21506, 18300318.
3. Hargrave DR, Hann IM. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, × and XI). Br J Haematol 2001, 112:293-299. 10.1046/j.1365-2141.2001.02543.x, 11167821.
4. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004, 22:4384-4393. 10.1200/JCO.2004.01.191, 15514380.
5. Ammann RA, Simon A, de Bont ES. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?. Pediatr Blood Cancer 2005, 45:244-247. 10.1002/pbc.20287, 15747334.
6. Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm JC. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Arch Dis Child 2007, 92:495-498. 10.1136/adc.2006.102699, 2066132, 17284481.
7. Boragina M, Patel H. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey. Pediatr Blood Cancer 2007, 48:521-526. 10.1002/pbc.20810, 16724314.
8. Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 2010, 46:2950-2964. 10.1016/j.ejca.2010.05.024, 2981857, 20621468.
9. Santolaya M, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994, 18:589-595. 10.1093/clinids/18.4.589, 8038314.
10. Nijhuis CO, Kamps WA, Daenen SMG, Gietema JA, van der Graaf WTA, Groen HJM, Vellenga E, ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ESJM. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005, 23:7437-7444. 10.1200/JCO.2004.00.5264, 16234511.
11. Lehrnbecher T, Fleischhack G, Hanisch M, Deinlein F, Simon A, Bernig T, Chanock SJ, Klingebiel T. Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Hematologica 2004, 89:234-236.
12. Stryjewski GR, Nylen ES, Bell MJ, Snider RH, Becker KL, Wu A, Lawlor C, Dalton H. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 2005, 6:129-135. 10.1097/01.PCC.0000149317.15274.48, 15730597.
13. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008, 36:396-407. 10.1007/s15010-008-7374-y, 18759057.
14. Hugle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, Daikeler T. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol 26:453-456.
15. Dubos F, Martinot A, Gendrel D, Breart G, Chalumeau M. Clinical decision rules for evaluating meningitis in children. Curr Opin Neurol 2009, 22:288-293. 10.1097/WCO.0b013e32832b240e, 19381086.
16. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997, 99:580-588. 10.1046/j.1365-2141.1997.4453255.x, 9401070.
17. Centre for Reviews and Dissemination Systematic Review: CRD's Guidance for Undertaking Reviews in Health Care 2009, York, UK: University of York, Centre for Reviews and Dissemination.
18. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999, 282:1061-1066. 10.1001/jama.282.11.1061, 10493205.
19. Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25. 10.1186/1471-2288-3-25, 305345, 14606960.
20. Centre for Reviews and Dissemination Systematic reviews of clinical tests. Systematic Review: CRD's Guidance for Undertaking Reviews in Health Care 2009, 109-156. Centre for Reviews and Dissemination. York, UK: University of York, Centre for Reviews and Dissemination.
21. Stata Statistical Software: Release 10. Stata Statistical Software: Release 10 2007, College Station, TX:StataCorp LP.
22. Harbord R. METANDI: Stata module to perform meta-analysis of diagnostic accuracy. METANDI: Stata Module to Perform Meta-analysis of Diagnostic Accuracy 2008, Bristol, UK: Department of Social Medicine, University of Bristol.
23. Dwamena BA. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies. MIDAS: Stata Module for Meta-analytical Integration of Diagnostic Test Accuracy Studies 2009, Chestnut Hill, MA: Boston College Department of Economics.
24. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature: III. How to use an article about a diagnostic test B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994, 271:703-707. 10.1001/jama.1994.03510330081039, 8309035.
25. Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
26. Ammann RA, Hirt A, Luthy AR, Aebi C. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003, 41:436-443. 10.1002/mpo.10320, 14515382.
27. El-Maghraby SM, Moneer MM, Ismail MM, Shalaby LM, El-Mahallawy HA. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol 2007, 29:131-136. 10.1097/MPH.0b013e3180308770, 17356388.
28. Hatzistilianou M, Rekleity A, Athanassiadou F, DeLutiis MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med 2007, 30:E75-85.
29. Hitoglou-Hatzi S, Hatzistilianou M, Gougoustamou D, Rekliti A, Agguridaki C, Athanassiadou F, Frydas S, Kotsis A, Catriu D. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med 2005, 5:60-65. 10.1007/s10238-005-0067-2, 16096855.
30. Katz JA, Mustafa MM, Bash RO, Cash JV, Buchanan GR. Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis J 1992, 11:708-712. 10.1097/00006454-199209000-00007, 1448309.
31. Kitanovski L, Jazbec J, Hojker S, Gubina M, Derganc M. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis 2006, 25:413-415. 10.1007/s10096-006-0143-x, 16767494.
32. Riikonen P, Jalanko H, Hovi L, Saarinen UM. Fever and neutropenia in children with cancer: diagnostic parameters at presentation. Acta Paediatr 1993, 82:271-275. 10.1111/j.1651-2227.1993.tb12658.x, 8495083.
33. Secmeer G, Devrim I, Kara A, Ceyhan M, Cengiz B, Kutluk T, Buyukpamukcu M, Yetgin S, Tuncer M, Uludag AK, Tezer H, Yildirim I. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol 2007, 29:107-111. 10.1097/MPH.0b013e3180320b5b, 17279007.
34. Santolaya ME, Alvarez AM, Becker A, Cofre J, Enriquez N, O'Ryan M, Paya E, Pilorget J, Salgado C, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001, 19:3415-3421.
35. Spasova MI, Terzieva DD, Tzvetkova TZ, Stoyanova AA, Mumdzhiev IN, Yanev IB, Genev ED. Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. Folia Med (Plovdiv) 2005, 47:46-52.
36. Riikonen P, Saarinen UM, Teppo AM, Metsarinne K, Fyhrquist F, Jalanko H. Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis 1992, 166:432-436. 10.1093/infdis/166.2.432, 1378873.
37. Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kuhl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999, 29:414-419. 10.1086/520224, 10476751.
38. Diepold M, Noellke P, Duffner U, Kontny U, Berner R. Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis 2008, 8:28. 10.1186/1471-2334-8-28, 2292194, 18321393.
39. Lehrnbecher T, Fleischhack G, Hanisch M, Deinlein F, Simon A, Bernig T, Chanock SJ, Klingebiel T. Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Haematologica 2004, 89:234-236.
40. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009, 100:1219-1229. 10.1038/sj.bjc.6604999, 2676559, 19367280.
41. Frakking FN, van de Wetering MD, Brouwer N, Dolman KM, Geissler J, Lemkes B, Caron HN, Kuijpers TW. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer 2006, 42:909-916. 10.1016/j.ejca.2005.10.027, 16517152.
42. Schlapbach LJ, Aebi C, Hansen AG, Hirt A, Jensenius JC, Ammann RA. H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. Clin Exp Immunol 2009, 157:83-89. 10.1111/j.1365-2249.2009.03957.x, 2710595, 19659773.
43. Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001, 54:774-781. 10.1016/S0895-4356(01)00341-9, 11470385.
44. Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13. 10.1186/1471-2288-5-13, 1097734, 15840177.
45. Kyzas PA, Denaxa-Kyza D, Ioannidis JPA. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007, 99:236-243. 10.1093/jnci/djk032, 17284718.
46. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004, 140:189-202.
47. Knudsen TB, Kristiansen TB. Issues pertaining to data extraction and classification and publication bias in meta analysis of the diagnostic accuracy of markers for bacterial infection. Clin Infect Dis 2005, 40:1372-1373. 10.1086/429507, 15825043.
48. Sanders S, Barnett A, Correa-Velez I, Coulthard M, Doust J. Systematic review of the diagnostic accuracy of c-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. J Pediatr 2008, 153:570-574. 10.1016/j.jpeds.2008.04.023, 18534215.
49. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217. 10.1086/421997, 15307030.
50. Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, Hansson LO, Tidefelt U. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004, 36:365-371. 10.1080/00365540410020217, 15287382.
51. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994, 69:979-985. 10.1038/bjc.1994.192, 1969431, 8198989.
52. de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 1999, 107:375-380. 10.1046/j.1365-2141.1999.01707.x, 10583227.
53. Oude Nijhuis C, Kamps WA, Daenen SMG, Gietema JA, van der Graaf WTA, Groen HJM, Vellenga E, Ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ESJM. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005, 23:7437-7444. 10.1200/JCO.2004.00.5264, 16234511.
54. Predicting Infectious Complications in Febrile Neutropenic Children with Cancer (PICNICC). , http://www.york.ac.uk/inst/crd/projects/picnicc_clinician.htm